Cryo-Save Group N.V. (Euronext: CRYO, `Cryo-Save`, or `the Group`), the leader in stem cell cryo-preservation and the largest stem cell bank in Europe, announces today that it has filed an application for a listing of its shares on Euronext Paris.
On 14 May 2014, the Group announced the intention to change the name of the company into Esperite N.V. and the implementation of an innovative growth and expansion strategy by entering into the fields of predictive medicine, translational regenerative medicine and related R&D activities. The creation of three independant yet synergistic business units aims to support the specialization of its operations. Today the Group announces that, as a further step in the transformation of its business, it has applied for a secondary Euronext Paris listing. Euronext Paris is currently the most active trading platform for public life sciences companies in Europe. The company considers the secondary Euronext Paris listing as a clear signal of its ambitions in the sector.
The company`s shareholders are expected to approve the change of the company`s formal name to Esperite N.V. during an extraordinary general meeting of shareholders to be held on 2 July 2014. The secondary Euronext Paris listing is expected to be effected shortly afterward.
The company`s primary listing on Euronext Amsterdam will continue and will act synergistically with the Euronext Paris listing, adding to the visibility of the Group. The company shall not be offering any new shares nor any other securities in connection with the Euronext Paris listing. In relation to the secondary Euronext Paris listing, a summary document shall be prepared, subject to the review of the Autorité des Marchés Financiers, the French regulator (the `AMF`), and made generally available in accordance with the General Regulations (Règlement général) of the AMF.
|Cryo-Save Group||+ 31 (0) 575 548 998|
|Frederic Amar, CEO|
About Cryo-Save (www.cryo-save.com/group)
Cryo-Save, the uncontested leader in stem cell cryo-preservation, stores more than 260,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Cryo-Save has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Portugal, Germany, Dubai, and South Africa.
The Group is now expanding its activities into the fields of translational regenerative medicine and proteomics and genomics predictive medicine.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cryo-Save Group N.V. via GlobeNewswire